- FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
- FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
- FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
- FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
Key statistics
On Tuesday, Fibrobiologics Inc (FBLG:NMQ) closed at 9.43, 44.41% above the 52 week low of 6.53 set on Feb 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.26 |
---|---|
High | 10.42 |
Low | 9.34 |
Bid | 9.17 |
Offer | 11.00 |
Previous close | 10.55 |
Average volume | 62.54k |
---|---|
Shares outstanding | 32.72m |
Free float | 22.79m |
P/E (TTM) | -- |
Market cap | 345.19m USD |
EPS (TTM) | -0.9149 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 21:00 BST.
More ▼